There are four ongoing phase 3 clinical trials considering anti-PD-1/PD-L1 ICIs for early-stage NSCLC patients after receiving complete tumor resection (ANVIL, PEARLS, IMpower010, and BR31) [78,102,103,104]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.